ES2175333T3 - Nueva administracion de trombopoyetina. - Google Patents

Nueva administracion de trombopoyetina.

Info

Publication number
ES2175333T3
ES2175333T3 ES97901434T ES97901434T ES2175333T3 ES 2175333 T3 ES2175333 T3 ES 2175333T3 ES 97901434 T ES97901434 T ES 97901434T ES 97901434 T ES97901434 T ES 97901434T ES 2175333 T3 ES2175333 T3 ES 2175333T3
Authority
ES
Spain
Prior art keywords
thrombopoietin
administration
low
materials
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901434T
Other languages
English (en)
Inventor
Griffith R Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2175333T3 publication Critical patent/ES2175333T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL HALLAZGO SORPRENDENTE E INESPERADO DE QUE MATERIALES DE TROMBOPOYETINA BIOLOGICAMENTE ACTIVOS PUEDEN ADMINISTRARSE CON UN EFECTO TERAPEUTICO SUSTANCIAL A DOSIFICACIONES COMPARABLES CON LA ADMINISTRACION DESCRITA ANTERIORMENTE DE DICHOS MATERIALES, PERO EN UNA ADMINISTRACION UNICA O DE DIAS MULTIPLES SEPARADOS. DE ESTE MODO, LA PRESENTE INVENCION SE REFIERE A LA REVERSION DE LA TROMBOCITOPENIA MEDIANTE LA ADMNISTRACION A UN PACIENTE QUE TENGA LA NECESIDAD DE DICHO TRATAMIENTO DE UNA DOSIS UNICA O DE DIAS MULTIPLES SEPARADOS DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UNA TROMBOPOYETINA. LA DOSIS PREFERIBLE DEL MATERIAL ACTIVO VA DE APROXIMADAMENTE 1 A APROXIMADAMENTE 10 MI G/KG DE PESO CORPORAL.
ES97901434T 1996-01-25 1997-01-13 Nueva administracion de trombopoyetina. Expired - Lifetime ES2175333T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59192596A 1996-01-25 1996-01-25
US64144396A 1996-04-29 1996-04-29
US08/697,631 US5879673A (en) 1996-01-25 1996-08-28 Administration of thrombopoietin on a single day only

Publications (1)

Publication Number Publication Date
ES2175333T3 true ES2175333T3 (es) 2002-11-16

Family

ID=27416624

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97901434T Expired - Lifetime ES2175333T3 (es) 1996-01-25 1997-01-13 Nueva administracion de trombopoyetina.
ES01123002T Expired - Lifetime ES2315255T3 (es) 1996-01-25 1997-01-13 Utilizacion de trombopoyetina como medicamento para la terapia y la prevencion de trombocitopenia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01123002T Expired - Lifetime ES2315255T3 (es) 1996-01-25 1997-01-13 Utilizacion de trombopoyetina como medicamento para la terapia y la prevencion de trombocitopenia.

Country Status (11)

Country Link
US (1) US5879673A (es)
EP (2) EP0876152B1 (es)
JP (1) JP2000504325A (es)
AT (2) ATE411039T1 (es)
AU (1) AU711639B2 (es)
CA (1) CA2242417A1 (es)
DE (2) DE69712036T2 (es)
DK (2) DK1201246T3 (es)
ES (2) ES2175333T3 (es)
PT (1) PT876152E (es)
WO (1) WO1997026907A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142940C (zh) * 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
AU2006201129B2 (en) * 1997-05-21 2008-03-13 Genentech, Inc. Novel administration of thrombopoietin
WO1999011262A1 (en) * 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
DE19956156A1 (de) * 1999-11-23 2001-06-13 Univ Eberhard Karls Verfahren zur Aufbereitung eines Präparates von Thrombozyten und Thrombozytenpräparat
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
HUP0303246A2 (hu) * 2001-02-23 2003-12-29 Immunex Corporation Aktív fehérjék fokozott kinyerése
DE10227606B3 (de) * 2002-06-20 2004-01-22 Bionethos Holding Gmbh Verwendung von Thrombopoietin zur Kultivierung von Hepatozyten
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
PL1636261T3 (pl) * 2003-06-26 2007-12-31 Merck Patent Gmbh Białka trombopoetynowe o ulepszonych właściwościach
EP1670821A4 (en) * 2003-10-09 2006-11-29 Daewoong Co Ltd PROCESS FOR THE PURIFICATION OF HUMAN THROMBOPOIETIN WITH A HIGH SIALIC ACID CONTENT
ES2606068T3 (es) 2003-12-30 2017-03-17 Augustinus Bader Eritropoyetina para uso en el tratamiento de heridas o el trasplante de células
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2013048402A1 (en) * 2011-09-29 2013-04-04 Mcw Research Foundation, Inc. Thrombopoietin receptor ligands for neuroprotection
CN102973922B (zh) * 2012-12-18 2016-02-03 华东理工大学 一种融合蛋白的应用
JP6050289B2 (ja) * 2013-07-11 2016-12-21 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011384A1 (en) * 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
DK0690127T3 (da) * 1994-03-31 1999-05-03 Amgen Inc Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
US5593666A (en) * 1994-08-16 1997-01-14 The University Of Tennessee Research Corp. Methods and compositions for treating thrombocytopenia
US6013067A (en) * 1995-06-07 2000-01-11 Zymogenetics, Inc. Methods for increasing hematopoietic cells

Also Published As

Publication number Publication date
DE69739050D1 (de) 2008-11-27
EP1201246B1 (en) 2008-10-15
EP0876152B1 (en) 2002-04-17
DE69712036D1 (de) 2002-05-23
ES2315255T3 (es) 2009-04-01
WO1997026907A1 (en) 1997-07-31
AU711639B2 (en) 1999-10-21
EP0876152A1 (en) 1998-11-11
ATE216257T1 (de) 2002-05-15
DK1201246T3 (da) 2009-02-23
PT876152E (pt) 2002-09-30
DE69712036T2 (de) 2002-11-28
ATE411039T1 (de) 2008-10-15
EP1201246A2 (en) 2002-05-02
AU1533597A (en) 1997-08-20
EP1201246A3 (en) 2002-05-08
JP2000504325A (ja) 2000-04-11
US5879673A (en) 1999-03-09
DK0876152T3 (da) 2002-08-12
CA2242417A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
ES2175333T3 (es) Nueva administracion de trombopoyetina.
RU2004106569A (ru) Способ применения антибиотиков
RU95113492A (ru) Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения
GEP20002146B (en) Therapeutic Peptide Derivatives
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
GR3025502T3 (en) Drugs, their manufacture, and their use as painkillers and/or to treat inflammations in humans and animals.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE69535801D1 (de) Beschleuniger des plättchenwachstums
JPS6483020A (en) Medicinal composition for preventing or treating aids
KR930021178A (ko) 뼈 형성을 자극하는 약제
RU95112520A (ru) Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
DE69618511D1 (de) Gammainterferon enthaltende Zusammensetzung zur Prurigo-Behandlung
KR930019207A (ko) 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도
DE69833317D1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
GEP20012366B (en) Thienyl-, Furil-, Pyrrolyl- and Biphenyl-Sulfonamides, Their Derivatives, Their Use in Medicinal Purposes, Pharmaceutical Composition Containing the Same and Method for Treatment

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 876152

Country of ref document: ES